The tetraCXP SYSTEM for the Cytomics FC 500 flow cytometry systems is an automated analysis method for simultaneous identification and enumeration of lymphocyte subpopulations (CD3+, CD4+, CD8+, CD19+and CD56+) combining four-color fluorescent monoclonal antibody reagents, quality control reagents, optional absolute count reagent and CXP software. The system with CYTO-STAT tetraCHROME CD45-FITC/CD4-PE/CD8-ECD/CD3-PC5 Monoclonal antibody reagent is intended "For In Vitro Diagnostic Use", allowing the identification and enumeration of Total CD3+ (T cells), Total CD4+, Total CD8+, Dual CD3+/CD4+, Dual CD3+/CD8+ lymphocyte percentages and absolute counts as well as the CD4/CD8 ratio in whole blood flow cytometry. The system with CD45-FITC/CD56-PE/CD19-ECD/CD3-PC5, the total lymphocyte percentage can be obtained. CD45-FITC/CD56-PE/CD19-ECD/CD3-PC5 monoclonal antibody reagent is intended "For In Vitro Diagnostic Use", allowing the identification and enumeration of total CD19+ (B cells) and CD3-/CD56+ (NK cells) lymphocyte percentages and absolute counts in whole blood flow cytometry. The total lymphocyte percentage can be obtained as well.

Device Description

tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software consists of CYTO-STAT tetraCHROME CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 and CYTO-STAT tetraCHROME CD-45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 monoclonal antibody reagents, quality control reagents, an optional absolute count reagent, and automated application and operating software on the Cytomics FC 500 Flow Cytometer.

AI/ML Overview

This document is a 510(k) Summary for the tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software. It describes a device intended for "in vitro diagnostic use" for the simultaneous identification and enumeration of lymphocyte subpopulations in whole blood.

Here's an analysis of the provided text in relation to your request:

Acceptance Criteria and Device Performance:

The document does not explicitly state quantitative acceptance criteria in a table format, nor does it provide detailed performance data for the tetraCXP system. Instead, it relies on demonstrating substantial equivalence to a predicate device. This is a common approach in 510(k) submissions, where a new device's safety and effectiveness are established by showing it is at least as safe and effective as a legally marketed predicate device.

The "Comparison to Predicate" table highlights similarities and differences between the new tetraCXP System and the predicate tetraONE System. The key similarity underpinning the substantial equivalence claim is the "Automated Analysis Algorithm": the tetraCXP System uses an algorithm described as "Based on cellSTAT 3D™ algorithm," which is the same as the predicate's "cellSTAT 3D™ algorithm." This implies that the core analytical performance is expected to be similar.

Missing Information:

Crucially, the provided text does not contain the detailed study data, acceptance criteria, or performance metrics that would typically be found in a comprehensive study report proving the device meets specific performance targets. The 510(k) summary is a high-level overview.

Based on the provided text, here's what can be extracted and what is missing:

1. Table of Acceptance Criteria and Reported Device Performance:

Acceptance Criteria: Not explicitly stated as quantitative targets in the provided document. The acceptance criterion is implied to be "substantially equivalent" to the predicate device's performance.
Reported Device Performance: No specific quantitative performance data (e.g., accuracy, precision, sensitivity, specificity, correlation coefficients) are reported in this summary. The device's performance is implicitly judged to be equivalent to the predicate due to the use of similar technology and algorithms.

2. Sample Size Used for the Test Set and Data Provenance:

Sample Size: Not specified in the provided text.
Data Provenance: Not specified (e.g., country of origin, retrospective or prospective).

3. Number of Experts Used to Establish Ground Truth and Qualifications:

Number of Experts: Not specified.
Qualifications of Experts: Not specified.

4. Adjudication Method for the Test Set:

Adjudication Method: Not specified.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

MRMC Study Done?: No, an MRMC comparative effectiveness study is not mentioned or described. This type of study is more common for imaging devices where human interpretation is a critical component, rather than for automated cell counters.
Effect Size of Human Reader Improvement with AI vs. Without AI: Not applicable, as this is an automated device and an MRMC study is not indicated.

6. Standalone (Algorithm Only) Performance:

Standalone Performance Done?: Yes, the entire device functions as a "standalone" automated analysis system. The text indicates "automated analysis of lymphocyte subpopulations" and "automated analysis algorithm," suggesting the algorithm operates without direct human intervention in the analysis process once the sample is loaded. However, no specific performance metrics for this standalone operation are provided in the summary.

7. Type of Ground Truth Used:

Type of Ground Truth: Not explicitly stated. For automated cell counters, the ground truth is typically established by manual differential counts performed by trained laboratory technologists (often on stained smears), or by comparison to a reference method (e.g., another established flow cytometry method). The document's claims of substantial equivalence to a predicate device imply that the predicate's established performance serves as a de-facto reference for expected accuracy, but the specifics of how the ground truth was established for this specific device's validation are not detailed.

8. Sample Size for the Training Set:

Sample Size: Not specified in the provided text.

9. How Ground Truth for the Training Set was Established:

How Ground Truth Established: Not specified in the provided text.

In summary:

The provided text is a 510(k) summary, which focuses on demonstrating substantial equivalence to a predicate device rather than presenting detailed study methodologies and performance statistics. While it implies that the device meets performance criteria by virtue of its similarity to a legally marketed device, it does not contain the specific information requested about acceptance criteria, detailed study design, sample sizes, expert involvement, or concrete performance data. This information would typically be found in the full 510(k) submission or associated validation reports, which are not included here.

Summary

{0}------------------------------------------------

K030828

510(k) Summary of Safety and Effectiveness for Section 1 D:

tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software

1.0	General Information
Applicant Name and Address:	Beckman Coulter, Inc.Cellular Analysis Division11800 SW 147 AvenueMiami, FL 33196-2500
Primary Contact:	Stan Sugrue, Ph.D.Senior Regulatory Affairs SpecialistTelephone: (305) 380-4552FAX: (305) 380-3618E-mail: stan.sugrue@coulter.com
Date:	March 13, 2003
Device Trade Name(s):	tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software
Device Generic Name(s):	Automated differential cell counter
Device Classification:	The tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software is a Class II medical device

2.0 Predicate Device

The tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software claims substantial equivalence to the tetraONE SYSTEM for EPICS XL Flow Cytometry SYSTEM with CYTO-STAT tetraCHROME CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 Monoclonal Antibody Reagent and CYTO-STAT tetraCHROME CD-45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 Monoclonal Antibody Reagent.

FDA 510(k) Number(s): K990172

3.0 Device Description

4.0 Principle of Method:

This test depends upon the ability of an monoclonal antibody to bind to the surface of cells expressing discrete antigenic determinants. Specific cell staining is accomplished by incubating whole blood with monoclonal antibody reagent. Red blood cells are lysed and the remaining white cells are analyzed on the FC 500 flow cytometry systems with CXP software and the tetraCXP SYSTEM (reagent application) software packages. The tetraCXP SYSTEM reagent application software, in conjunction with CXP operating system software on the FC 500 flow cytometer, tetraCHROME monoclonal antibody reagents, provides automated analysis of lymphocyte subpopulations.

{1}------------------------------------------------

5 0 Comparison to Predicate

Comparison	Characteristic	tetraONE System(Predicate)	tetraCXP System
Similarities	Intended Use	Enumeration of total T, B, and NK lymphocytes and three major lymphocyte subset populations	Same as tetraONE
	Analysis Reagents	CYTO-STAT®tetraCHROME™ CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5	Same as tetraONE
		CYTO-STAT®tetraCHROME™ CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5Flow-Count™ Fluorospheres
	AutoSetup Reagents	Flow-Set™ FluorospheresCYTO-COMP™ Cell Kit	Same as tetraONE
	QC Reagents	CYTO-TROL™ Control Cells orIMMUNO-TROL™ CellsIMMUNO-TROL™ Low Cells	Same as tetraONE
	Automated AnalysisAlgorithm	cellSTAT 3D™ algorithm	Based on cellSTAT 3D™algorithm
Differences	Flow Cytometer	EPICS® XL-MCL™ flowcytometry system	CYTOMICS FC 500 flowcytometry system
	System Software	System II	CXP
	AutoSetup Reagents	CYTO-COMP™Reagent Kit	QuickCOMP 4 Kit

6.0 Indications for Use:

7.0 Conclusion:

The tetraCXP SYSTEM for the Cytomics FC 500 flow cytometry systems is substantially equivalent to the previously cleared tetraONE System for EPICS XL Flow Cytometry System with CYTO-STAT® tetraCHROME™ CD45-FITC/CD4-PE/CD8-ECD/CD3-PC5 Monoclonal Antibody Reagent and CYTO-STAT® tetraCHROME™ CD45-FITC/CD56-PE/CD19-ECD/CD3-PC5 Monoclonal Antibody Reagent.

{2}------------------------------------------------

Section 1 F:

Submitted By 1.0

Beckman Coulter, Inc. Cellular Analysis Division 11800 SW 147 Avenue Miami, FL 33196-2500

Primary Contact: Stan Sugrue, Ph.D. Senior Regulatory Affairs Specialist Telephone: (305) 380-4552 FAX: (305) 380-3618 E-mail: stan.sugrue@coulter.com

Secondary Contact: Deborah Herrera Group Manager, Requlatory Affairs Telephone: (305) 380-4013 FAX: (305) 380-3618 E-mail: debbie.herrera@coulter.com

2.0 Sponsor Address/FDA Registration Number

Beckman Coulter, Inc. Cytomics Division 11800 SW 147 Avenue Miami. FL 33196-2500 FDA Establishment Registration: 1061932

3.0 Device Name(s)/Classification Name and Number

Device Trade Name(s): tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software

Classification Name and Number: Automated differential cell counter : 21 CFR 864.5220

4.0 Device Classification

The Hematology Panel has classified Automated differential cell counters as Class II, (81 GKZ) devices.

Section 514 Compliance 5.0

This Abbreviated 510(k) submission is prepared in accordance with FDA publication : The New 510(k) Paradigm: Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications-Issue Date: March 20, 1998. It claims compliance with the FDA publication: Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood cells; Final Guidance for Industry and FDA- Issue Date: December 4, 2001.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services USA. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing right, with flowing lines suggesting movement or connection.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Stan Sugrue, Ph.D. Senior Regulatory Affairs Specialist Beckman Coulter, Inc. Cellular Analysis Division 11800 SW 147 Avenue Miami. Florida 33196-2500

MAY 21 2003

Re: K030828

Trade/Device Name: tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software Regulation Number: 21 CFR § 864.5220 Regulation Name: Automated differential cell counter Regulatory Class: II Product Code: GKZ Dated: March 13, 2003 Received: March 14, 2003

Dear Dr. Sugrue:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

{4}------------------------------------------------

Page 2 –

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Section 1C:

INDICATIONS FOR USE

K030828

510(k) Number (if known): Not assigned

Device:

tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software

The tetraCXP Software for Cytomics FC 500 flow cytometry systems and CYTO-STAT tetraCHROME™ CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 and CYTO-STAT tetraCHROME™ CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 Monoclonal Antibody Reagents combine four-color fluorescent monoclonal antibody reagents, quality control reagents, an optional absolute count reagent, and software for automated analysis of lymphocyte populations in whole blood using Cytomics FC 500 flow cytometry systems with CXP Software.

The system with CYTO-STAT tetraCHROME CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 is intended "For In Vitro Diagnostic Use" and allows simultaneous identification and enumeration of total CD3+, total CD4+, total CD8+, dual CD3+/CD4+ and dual CD3+/CD8+ T lymphocyte population percentages and absolute counts.

The system with CYTO-STAT tetraCHROME CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 is intended "For In Vitro Diagnostic Use" and allows simultaneous identification and enumeration of total CD3+ (T), CD19+ (B), and CD3-/CD56+ (NK) lymphocyte population percentages and absolute counts. This reagent reflects the distribution of the three major subsets comprising the lymphocyte population upon which other lymphocyte enumeration studies are based and provides the total lymphocyte percentage.

21 CFR 864.5220 Automated differential cell counter

An automated differential cell counter is a device used to identify and classify one or more of the formed elements of blood.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use " Use (Per 21 CFR 801.109)

Over-The-Counter

Rosalina Bautista

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number	K0 30828

Beckman Coulter, Inc. tetra CXP SYSTEM

Regulation Number and Section

§ 864.5220 Automated differential cell counter.

(a)
Identification. An automated differential cell counter is a device used to identify one or more of the formed elements of the blood. The device may also have the capability to flag, count, or classify immature or abnormal hematopoietic cells of the blood, bone marrow, or other body fluids. These devices may combine an electronic particle counting method, optical method, or a flow cytometric method utilizing monoclonal CD (cluster designation) markers. The device includes accessory CD markers.(b)
Classification. Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA.”